Avanza Fonder AB Takes Position in Astera Labs, Inc. $ALAB

Avanza Fonder AB acquired a new position in Astera Labs, Inc. (NASDAQ:ALAB) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,151 shares of the company’s stock, valued at approximately $857,000.

A number of other large investors have also recently bought and sold shares of ALAB. Clearstead Advisors LLC increased its holdings in Astera Labs by 13.6% in the 3rd quarter. Clearstead Advisors LLC now owns 636 shares of the company’s stock worth $125,000 after buying an additional 76 shares during the period. Great Valley Advisor Group Inc. raised its position in Astera Labs by 2.2% during the 2nd quarter. Great Valley Advisor Group Inc. now owns 4,119 shares of the company’s stock worth $372,000 after buying an additional 90 shares during the last quarter. Rye Brook Capital LLC lifted its stake in Astera Labs by 1.1% during the 3rd quarter. Rye Brook Capital LLC now owns 9,200 shares of the company’s stock valued at $1,801,000 after acquiring an additional 100 shares during the period. Hilltop National Bank boosted its holdings in shares of Astera Labs by 100.0% in the 4th quarter. Hilltop National Bank now owns 200 shares of the company’s stock valued at $33,000 after acquiring an additional 100 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in shares of Astera Labs by 374.1% in the 3rd quarter. Assetmark Inc. now owns 128 shares of the company’s stock valued at $25,000 after acquiring an additional 101 shares during the last quarter. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Astera Labs Price Performance

NASDAQ:ALAB opened at $121.76 on Wednesday. The firm has a market cap of $20.85 billion, a price-to-earnings ratio of 99.80, a price-to-earnings-growth ratio of 2.44 and a beta of 1.74. The company has a 50 day moving average price of $141.95 and a 200-day moving average price of $165.11. Astera Labs, Inc. has a 1-year low of $47.13 and a 1-year high of $262.90.

Astera Labs (NASDAQ:ALAB) last announced its quarterly earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.07. The firm had revenue of $270.58 million for the quarter, compared to the consensus estimate of $249.46 million. Astera Labs had a net margin of 25.70% and a return on equity of 16.12%. The firm’s quarterly revenue was up 91.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.37 earnings per share. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. On average, sell-side analysts anticipate that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jack R. Lazar sold 7,500 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $119.80, for a total transaction of $898,500.00. Following the sale, the director directly owned 87,351 shares in the company, valued at $10,464,649.80. This trade represents a 7.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Truett Tate sold 12,001 shares of Astera Labs stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $123.81, for a total value of $1,485,843.81. Following the completion of the transaction, the chief financial officer owned 192,083 shares of the company’s stock, valued at approximately $23,781,796.23. This represents a 5.88% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 384,292 shares of company stock valued at $48,724,919. Insiders own 12.50% of the company’s stock.

Trending Headlines about Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Company benefits from robust AI infrastructure demand — management/product roadmaps (Scorpio, Aries, Taurus) and hyperscaler spend are cited as growth drivers for 2026, supporting revenue momentum and longer‑term upside. ALAB Benefits From Strong AI Infrastructure Demand: What’s Ahead?
• Positive Sentiment: Index inclusion and a new shelf filing improve the stock’s public market profile — FTSE All‑World inclusion can create passive fund flows, while a shelf gives management optionality to raise capital if needed. Astera Labs Index Entry And Shelf Filing Shape Capital Access Story
• Neutral Sentiment: Management presented at the Roth conference — the transcript provides additional detail on strategy and product roadmap but contains no new market‑moving surprises. Astera Labs, Inc. (ALAB) Presents at The 38th Annual Roth Conference Transcript
• Neutral Sentiment: Market writeups explaining today’s dip summarize mixed technicals/valuation and short‑term profit‑taking rather than a single fundamental shock. Why Astera Labs, Inc. (ALAB) Dipped More Than Broader Market Today
• Negative Sentiment: Short interest has risen materially (reported ~13.5M shares as of Mar. 13, ~9.1% of shares sold short, ~2.8 days to cover) — higher short positioning increases downside pressure and volatility on negative news or further technical selling.
• Negative Sentiment: Analyst/commentary pieces flag a recent pullback and question near‑term valuation after a strong prior run; that bearish tone can reinforce selling among momentum traders. Is It Too Early To Reconsider Astera Labs (ALAB) After Recent Share Price Pullback

Analyst Ratings Changes

Several research analysts recently issued reports on ALAB shares. Loop Capital started coverage on shares of Astera Labs in a report on Thursday, March 5th. They set a “buy” rating and a $250.00 target price for the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astera Labs in a report on Wednesday, December 3rd. Northland Securities increased their price target on Astera Labs from $175.00 to $195.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Morgan Stanley reiterated an “overweight” rating and set a $210.00 price objective on shares of Astera Labs in a research note on Wednesday, December 3rd. Finally, Weiss Ratings cut Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 23rd. Fifteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $202.22.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.